Tami Tillotson Martin Sells 5,000 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPNGet Rating) VP Tami Tillotson Martin sold 5,000 shares of the stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $32.98, for a total value of $164,900.00. Following the completion of the sale, the vice president now owns 87,220 shares in the company, valued at approximately $2,876,515.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN traded down $0.65 during trading hours on Friday, reaching $32.16. 652,235 shares of the stock traded hands, compared to its average volume of 416,375. The stock has a 50 day simple moving average of $29.11 and a two-hundred day simple moving average of $29.79. Supernus Pharmaceuticals, Inc. has a 1 year low of $23.15 and a 1 year high of $34.50. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.00 and a quick ratio of 1.69. The company has a market cap of $1.72 billion, a price-to-earnings ratio of 24.74 and a beta of 1.04.

Supernus Pharmaceuticals (NASDAQ:SUPNGet Rating) last released its quarterly earnings results on Thursday, August 4th. The specialty pharmaceutical company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.15). Supernus Pharmaceuticals had a net margin of 12.20% and a return on equity of 9.05%. The firm had revenue of $170.10 million for the quarter, compared to analysts’ expectations of $164.23 million. During the same quarter in the previous year, the business earned $0.43 EPS. The company’s revenue for the quarter was up 20.4% on a year-over-year basis. On average, analysts predict that Supernus Pharmaceuticals, Inc. will post 1.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. UMB Bank N A MO bought a new position in shares of Supernus Pharmaceuticals during the fourth quarter valued at about $29,000. First Horizon Advisors Inc. bought a new position in shares of Supernus Pharmaceuticals during the second quarter valued at about $34,000. C M Bidwell & Associates Ltd. bought a new position in shares of Supernus Pharmaceuticals during the fourth quarter valued at about $43,000. Captrust Financial Advisors grew its stake in shares of Supernus Pharmaceuticals by 163.3% during the first quarter. Captrust Financial Advisors now owns 2,983 shares of the specialty pharmaceutical company’s stock valued at $96,000 after buying an additional 1,850 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its stake in shares of Supernus Pharmaceuticals by 28.4% during the second quarter. Nisa Investment Advisors LLC now owns 3,390 shares of the specialty pharmaceutical company’s stock valued at $98,000 after buying an additional 750 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on SUPN shares. StockNews.com upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 18th. TheStreet downgraded Supernus Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Monday, April 18th.

About Supernus Pharmaceuticals

(Get Rating)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.

Read More

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.